Daiichi Sankyo Selects IntraLinks for Secure Information Sharing
TOKYO, January 19, 2010
－
IntraLinks
, a provider of critical information exchange solutions, announced that Daiichi Sankyo has selected IntraLinks as the company’s information sharing solution. Daiichi Sankyo now joins the world’s top 10 pharmaceutical companies that already leverage IntraLinks’ solution.
Daiichi Sankyo faces many new challenges including developing new innovative pharmaceuticals and ongoing communication with global regulatory bodies. Prior to selecting IntraLinks, Daiichi Sankyo considered a number of information sharing platforms for managing their highly confidential business information in a multi-lingual environment without imposing additional demand on the company’s IT resources. With IntraLinks, Daiichi Sankyo now manages, organizes, tracks and shares critical information both inside and outside the enterprise with 24/7/365 live system support around the world.
“We are extremely pleased to introduce the IntraLinks solution to facilitate secure and speedy information exchange inside and outside the company’s firewall. We plan to use IntraLinks strategically across diverse departments in the near future to raise our standard of operational efficiency,” said Mr. Yasuhiro Ikeda, General Manager, IT Strategy Department of Daiichi Sankyo.
“We are delighted that IntraLinks has been selected by Daiichi Sankyo. As a Software-as-a-Service solution, IntraLinks requires no additional hardware, software, or additional demands on IT resources. Hence our customers can gain tremendous cost efficiencies with a solution that can be implemented in near real-time. We believe the decision by Daiichi Sankyo is yet another testament to the effectiveness of our solution, which has already been widely deployed within the pharmaceutical industry,” said Rob Mullen, EVP of Worldwide Sales for IntraLinks.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
